IMPACT OF CARRIAGE OF 4G/5G PAI-1 AND GLYCOPROTEIN IIB/IIIA POLYMORPHISM ON DEVELOPMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PATIENT WITH PSORIASIS VULGARIS. Clinical Case.

• Main Authors: Borislav Dimitrov, Kalina Ilieva, Dimitar Gospodinov, Regina Komsa-Penkova
• Format: Article
• Language: English
• Published: Peytchinski Publishing 2019-05-01
• Series: Journal of IMAB
• Subjects: also affects many other tissues and organs. Recent advances in psoriatic research highlighted that psoriatic patients are at higher risk to develop the chronic obstructive pulmonary disease (COPD). We report a case of a Caucasian man of 62 years’ age with plaque psoriasis diagnosed more than 20 years who developed psoriasis specific comorbidities: COPD in 2005 and later in 2006 arterial hypertension and ischemic cardiomyopathy disease. The patient’s blood parameters were specific for psoriasis and metabolic syndrome with high total cholesterol 6.13 mmol/L; high triglycerides 2.37 mmol/L; high LDL 4.7 mmol/L; low HDL-cholesterol 0.79 mmol/L. Enzyme-linked immunosorbent assay (ELISA) analysis demonstrated elevated serum plasminogen activator inhibitor 1 (PAI-1) levels – 63.21 ng/ml (ref.5-40 ng/mL). The DNA analysis revealed a carriage of heterozygous polymorphism in PAI-1 4G/5G and a carriage of heterozygous polymorphism PlA1/PlA2 in the gene for glycoprotein IIb/IIIa. This case on psoriasis and comorbidity is an example concerning the possible connection of impact of inherited factors with an increased risk of COPD.; psoriasis; COPD; ischaemic heart disease; 4G/5G PAI-1; PlA1/PlA2
• Online Access: https://www.journal-imab-bg.org/issues-2019/issue2/JofIMAB-2019-25-2p2537-2543.pdf

Psoriasis vulgaris represents a chronic immune-inflammatory condition that besides skin and joints, also affects many other tissues and organs. Recent advances in psoriatic research highlighted that psoriatic patients are at higher risk to develop the chronic obstructive pulmonary disease (COPD). We report a case of a Caucasian man of 62 years’ age with plaque psoriasis diagnosed more than 20 years who developed psoriasis specific comorbidities: COPD in 2005 and later in 2006 arterial hypertension and ischemic cardiomyopathy disease. The patient’s blood parameters were specific for psoriasis and metabolic syndrome with high total cholesterol 6.13 mmol/L, high triglycerides 2.37 mmol/L, high LDL 4.7 mmol/L, low HDL-cholesterol 0.79 mmol/L. Enzyme-linked immunosorbent assay (ELISA) analysis demonstrated elevated serum plasminogen activator inhibitor 1 (PAI-1) levels – 63.21 ng/ml (ref.5-40 ng/mL). The DNA analysis revealed a carriage of heterozygous polymorphism in PAI-1 4G/5G and a carriage of heterozygous polymorphism PlA1/PlA2 in the gene for glycoprotein IIb/IIIa. This case on psoriasis and comorbidity is an example concerning the possible connection of impact of inherited factors with an increased risk of COPD.